Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Usefulness of Dual Immunohistochemistry Staining in Detection of Hairy Cell Leukemia in Bone Marrow.

Gupta GK, Sun X, Yuan CM, Stetler-Stevenson M, Kreitman RJ, Maric I.

Am J Clin Pathol. 2019 Oct 28. pii: aqz171. doi: 10.1093/ajcp/aqz171. [Epub ahead of print]

PMID:
31665200
2.

Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.

Kreitman RJ, Pastan I.

Oncologist. 2019 Oct 18. pii: theoncologist.2019-0370. doi: 10.1634/theoncologist.2019-0370. [Epub ahead of print]

PMID:
31628266
3.

Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia.

Feurtado J, Kreitman RJ.

Clin J Oncol Nurs. 2019 Jun 1;23(3):E52-E59. doi: 10.1188/19.CJON.E52-E59.

4.

Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.

Salem DA, Scott D, McCoy CS, Liewehr DJ, Venzon DJ, Arons E, Kreitman RJ, Stetler-Stevenson M, Yuan CM.

Cytometry B Clin Cytom. 2019 Jul;96(4):275-282. doi: 10.1002/cyto.b.21785. Epub 2019 May 11.

PMID:
31077558
5.

Hairy cell leukemia: present and future directions.

Kreitman RJ.

Leuk Lymphoma. 2019 Dec;60(12):2869-2879. doi: 10.1080/10428194.2019.1608536. Epub 2019 May 9.

PMID:
31068044
6.

Immunotoxins Targeting B cell Malignancy-Progress and Problems With Immunogenicity.

Vallera DA, Kreitman RJ.

Biomedicines. 2018 Dec 21;7(1). pii: E1. doi: 10.3390/biomedicines7010001. Review.

7.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.

8.

Update on hairy cell leukemia.

Kreitman RJ, Arons E.

Clin Adv Hematol Oncol. 2018 Mar;16(3):205-215. Review.

9.

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.

Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I.

Blood. 2018 May 24;131(21):2331-2334. doi: 10.1182/blood-2017-09-803072. Epub 2018 Feb 27.

10.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B.

J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26.

11.

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.

Wayne AS, Shah NN, Bhojwani D, Silverman LB, Whitlock JA, Stetler-Stevenson M, Sun W, Liang M, Yang J, Kreitman RJ, Lanasa MC, Pastan I.

Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.

12.

Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.

Antignani A, Segal D, Simon N, Kreitman RJ, Huang D, FitzGerald DJ.

Oncogene. 2017 Aug 31;36(35):4953-4962. doi: 10.1038/onc.2017.111. Epub 2017 Apr 24.

PMID:
28436946
13.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

14.

Immunoconjugates in the management of hairy cell leukemia.

Kreitman RJ, Pastan I.

Best Pract Res Clin Haematol. 2015 Dec;28(4):236-45. doi: 10.1016/j.beha.2015.09.003. Epub 2015 Oct 9. Review.

15.

Cladribine Analogues via O⁶-(Benzotriazolyl) Derivatives of Guanine Nucleosides.

Satishkumar S, Vuram PK, Relangi SS, Gurram V, Zhou H, Kreitman RJ, Montemayor MM, Yang L, Kaliyaperumal M, Sharma S, Pottabathini N, Lakshman MK.

Molecules. 2015 Oct 9;20(10):18437-63. doi: 10.3390/molecules201018437.

16.

Impact of telomere length on survival in classic and variant hairy cell leukemia.

Arons E, Zhou H, Edelman DC, Gomez A, Steinberg SM, Petersen D, Wang Y, Meltzer PS, Kreitman RJ.

Leuk Res. 2015 Dec;39(12):1360-6. doi: 10.1016/j.leukres.2015.09.015. Epub 2015 Sep 24.

17.

Cladribine Analogues via O⁶-(Benzotriazolyl) Derivatives of Guanine Nucleosides.

Satishkumar S, Vuram PK, Relangi SS, Gurram V, Zhou H, Kreitman RJ, Martínez Montemayor MM, Yang L, Kaliyaperumal M, Sharma S, Pottabathini N, Lakshman MK.

Molecules. 2015 Oct 9;20(10):18437-63. doi: 10.3390/molecules201018437.

18.

Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.

Kreitman RJ, Stetler-Stevenson M, Jaffe ES, Conlon KC, Steinberg SM, Wilson W, Waldmann TA, Pastan I.

Clin Cancer Res. 2016 Jan 15;22(2):310-8. doi: 10.1158/1078-0432.CCR-15-1412. Epub 2015 Sep 8.

19.

Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.

Weldon JE, Skarzynski M, Therres JA, Ostovitz JR, Zhou H, Kreitman RJ, Pastan I.

Bioconjug Chem. 2015 Jun 17;26(6):1120-8. doi: 10.1021/acs.bioconjchem.5b00190. Epub 2015 Jun 3.

PMID:
25997032
20.

Characterization of CD22 expression in acute lymphoblastic leukemia.

Shah NN, Stevenson MS, Yuan CM, Richards K, Delbrook C, Kreitman RJ, Pastan I, Wayne AS.

Pediatr Blood Cancer. 2015 Jun;62(6):964-9. doi: 10.1002/pbc.25410. Epub 2015 Mar 1.

21.

Removing a hair of doubt about BRAF targeting.

Kreitman RJ.

Blood. 2015 Feb 19;125(8):1199-200. doi: 10.1182/blood-2014-12-616318.

22.

Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model.

Pak Y, Pastan I, Kreitman RJ, Lee B.

PLoS One. 2014 Oct 24;9(10):e110716. doi: 10.1371/journal.pone.0110716. eCollection 2014.

23.

An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.

Bera TK, Onda M, Kreitman RJ, Pastan I.

Leuk Res. 2014 Oct;38(10):1224-9. doi: 10.1016/j.leukres.2014.06.014. Epub 2014 Jul 5.

24.

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.

Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.

Cancer. 2014 Nov 1;120(21):3311-9. doi: 10.1002/cncr.28875. Epub 2014 Jul 2.

25.

Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.

Arons E, Adams S, Venzon DJ, Pastan I, Kreitman RJ.

Br J Haematol. 2014 Sep;166(5):729-38. doi: 10.1111/bjh.12956. Epub 2014 Jun 13.

26.

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.

Mazor R, Eberle JA, Hu X, Vassall AN, Onda M, Beers R, Lee EC, Kreitman RJ, Lee B, Baker D, King C, Hassan R, Benhar I, Pastan I.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8571-6. doi: 10.1073/pnas.1405153111. Epub 2014 May 5.

27.

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.

Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA.

Br J Haematol. 2014 Jul;166(2):177-88. doi: 10.1111/bjh.12867. Epub 2014 Apr 2.

28.

Immunotoxins for leukemia.

Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I.

Blood. 2014 Apr 17;123(16):2470-7. doi: 10.1182/blood-2014-01-492256. Epub 2014 Feb 27. Review.

29.

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.

Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M.

Clin Cancer Res. 2013 Dec 15;19(24):6873-81. doi: 10.1158/1078-0432.CCR-13-1752. Epub 2013 Nov 25.

30.

High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.

Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS.

Nat Genet. 2014 Jan;46(1):8-10. doi: 10.1038/ng.2828. Epub 2013 Nov 17.

31.

Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.

Tembhare PR, Marti G, Wiestner A, Degheidy H, Farooqui M, Kreitman RJ, Jasper GA, Yuan CM, Liewehr D, Venzon D, Stetler-Stevenson M.

Am J Clin Pathol. 2013 Dec;140(6):813-8. doi: 10.1309/AJCPYFQ4XMGJD6TI.

32.

Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.

Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.

Sci Transl Med. 2013 Oct 23;5(208):208ra147. doi: 10.1126/scitranslmed.3006941.

33.

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.

Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ.

Clin Cancer Res. 2013 Nov 15;19(22):6313-21. doi: 10.1158/1078-0432.CCR-13-1848. Epub 2013 Oct 4.

34.

Hairy cell leukemia-new genes, new targets.

Kreitman RJ.

Curr Hematol Malig Rep. 2013 Sep;8(3):184-95. doi: 10.1007/s11899-013-0167-0. Review.

PMID:
23892906
35.

Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.

Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM.

Leuk Res. 2013 Apr;37(4):401-409. doi: 10.1016/j.leukres.2012.11.021. Epub 2013 Jan 22.

36.

Immunoconjugates and new molecular targets in hairy cell leukemia.

Kreitman RJ.

Hematology Am Soc Hematol Educ Program. 2012;2012:660-6. doi: 10.1182/asheducation-2012.1.660. Review.

37.

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.

Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I.

Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11782-7. doi: 10.1073/pnas.1209292109. Epub 2012 Jul 2.

38.

Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.

Simone CB 2nd, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ, Lita E, Conlon K, Wharfe G, Waldmann TA, Kaushal A.

Blood. 2012 Aug 30;120(9):1816-9. doi: 10.1182/blood-2012-01-401349. Epub 2012 Jun 22.

39.

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.

J Clin Oncol. 2012 May 20;30(15):1822-8. doi: 10.1200/JCO.2011.38.1756. Epub 2012 Feb 21.

40.

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.

Blood. 2012 Apr 5;119(14):3330-2. doi: 10.1182/blood-2011-09-379339. Epub 2011 Dec 30.

41.

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, Kreitman RJ, Peschel C, Pastan I, Meyer Zum Büschenfelde C, Ringshausen I.

Haematologica. 2012 May;97(5):771-9. doi: 10.3324/haematol.2011.049155. Epub 2011 Dec 16.

42.

Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

Singh R, Zhang Y, Pastan I, Kreitman RJ.

Clin Cancer Res. 2012 Jan 1;18(1):152-60. doi: 10.1158/1078-0432.CCR-11-1839. Epub 2011 Nov 8.

43.

The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.

Kawa S, Onda M, Ho M, Kreitman RJ, Bera TK, Pastan I.

MAbs. 2011 Sep-Oct;3(5):479-86. doi: 10.4161/mabs.3.5.17228. Epub 2011 Sep 1.

44.

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Kreitman RJ, Pastan I.

Clin Cancer Res. 2011 Oct 15;17(20):6398-405. doi: 10.1158/1078-0432.CCR-11-0487. Review.

45.

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.

FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I.

Cancer Res. 2011 Oct 15;71(20):6300-9. doi: 10.1158/0008-5472.CAN-11-1374. Review.

46.

Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders.

Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M.

Am J Clin Pathol. 2011 Oct;136(4):625-30. doi: 10.1309/AJCPKUM9J4IXCWEU.

PMID:
21917686
47.

Thrombotic microangiopathy with targeted cancer agents.

Blake-Haskins JA, Lechleider RJ, Kreitman RJ.

Clin Cancer Res. 2011 Sep 15;17(18):5858-66. doi: 10.1158/1078-0432.CCR-11-0804. Epub 2011 Aug 3. Review.

48.

Synergistic targeting of leukemia with leukotoxin and chemotherapy.

Kreitman RJ.

Leuk Res. 2011 Nov;35(11):1438-9. doi: 10.1016/j.leukres.2011.06.028. Epub 2011 Jul 20. No abstract available.

PMID:
21764132
49.

Molecular variant of hairy cell leukemia with poor prognosis.

Arons E, Kreitman RJ.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:99-102. doi: 10.3109/10428194.2011.565841.

PMID:
21599610
50.

Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.

Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:82-6. doi: 10.3109/10428194.2011.565843. Review.

PMID:
21599609

Supplemental Content

Loading ...
Support Center